The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States

Alimentary Pharmacology and Therapeutics

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2g6cD8R
via IFTTT